<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2022-09-03</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2823</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>Hepcidin as a Regulator of Iron Metabolism and Mediator of Inflammation in Patients with Chronic Heart Failure and Anemia of Chronic Diseases of the Elderly and Senile Age</article-title><trans-title-group xml:lang="ru"><trans-title>Гепсидин как регулятор метаболизма железа и медиатор воспаления у больных пожилого и старческого возраста с хронической сердечной недостаточностью и анемией хронических заболеваний</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4004-7802</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соломахина</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Solomakhina</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Соломахина Нина Иосифовна</p><p> Москва </p></bio><bio xml:lang="en"><p> Nina I. Solomakhina</p><p> Moscow </p><p> </p></bio><email xlink:type="simple">nina.gelman@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3391-0193</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лишута</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Lishuta</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лишута Алексей Сергеевич</p><p>eLibrary SPIN4365-4788</p><p>Москва </p></bio><bio xml:lang="en"><p> Alexey S. Lishuta </p><p>  Moscow </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5231-371X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дементьева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dementieva</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Дементьева Анна Викторовна</p><p> Москва </p></bio><bio xml:lang="en"><p> Anna V. Dementieva </p><p> Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУЗ «Госпиталь для Ветеранов Войн №1 Департамента здравоохранения Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Hospital for War Veterans No. 1 of the Moscow Department of Health</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2022</year></pub-date><volume>18</volume><issue>5</issue><fpage>553</fpage><lpage>563</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Solomakhina N.I., Lishuta A.S., Dementieva A.V., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Соломахина Н.И., Лишута А.С., Дементьева А.В.</copyright-holder><copyright-holder xml:lang="en">Solomakhina N.I., Lishuta A.S., Dementieva A.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2823">https://www.rpcardio.online/jour/article/view/2823</self-uri><abstract><p>Aim. To study the role of hepcidin as a regulator of iron metabolism and a mediator of inflammation in elderly and senile patients with chronic heart failure (CHF) with anemia of chronic diseases (ACD).Material and methods. The levels of hemogram parameters, ferrokinetics (serum iron, ferritin, transferrin, erythropoietin, hepcidin), inflammation [C-reactive protein (CRP), interleukin-6 (IL-6)], as well as correlations between hepcidin and these parameters were studied in patients with CHF with ACD (n=35), with CHF without anemia (n=35) and in elderly and senile patients without CHF and anemia (control group; n=20).Results. Normal levels of hepcidin (9.17±0.97 ng/ml) and the only significant correlation of hepcidin with the ferrokinetic parameter – serum iron [r(S)=0.480, p&lt;0.05] were found in the control group. Normal levels of hepcidin (12.01±1.19 ng/ml) and two significant correlations of hepcidin with the ferrokinetic parameter – ferritin [r(S)=0.525, p&lt;0.05] and transferrin [r(S)=-0.343, p&lt;0.05] were found in the CHF without anemia group. Significantly elevated levels of hepcidin (23.81±3.63 ng/ml) were found in the CHF with ACD group compared to the CHF without anemia group (p=0.008) and the control group (p=0.003). Also, five significant correlations of hepcidin with hemogram parameters – hemoglobin [r(S)=-0.461, p&lt;0.05] and the average concentration of hemoglobin in the erythrocyte [r(S)=-0.437, p&lt;0.05]; with ferrokinetic parameters – ferritin [r(S)=0.596,p&lt;0.05] and transferrin [r(S)=-0.474, p&lt;0.05]; with inflammation parameters – CRP [r(S)=0.561, p&lt;0.05] were found in the CHF with ACD group.Conclusion. The increased level of hepcidin in CHF patients with ACD and the formation of links of hepcidin with indicators of inflammation reflect its role as a mediator of inflammation, and the formation of connections with indicators of hemogram and ferrokinetics – its role as a regulator of iron metabolism involved in the development of ACD in elderly and senile CHF patients.</p></abstract><trans-abstract xml:lang="ru"><p>Цель. Изучить роль гепсидина как регулятора метаболизма железа и медиатора воспаления у больных пожилого и старческого возраста с хронической сердечной недостаточностью (ХСН) и анемией хронических заболеваний (АХЗ).Материал и методы. У 35 больных ХСН с АХЗ, 35 больных ХСН без анемии и 20 пациентов без ХСН и анемии (контрольная группа) пожилого и старческого возраста исследовали уровни показателей гемограммы, феррокинетики (сывороточное железо, ферритин, трансферрин, эритропоэтин, гепсидин), воспаления [С-реактивный белок (СРБ), интерлейкин-6 (ИЛ-6)] и связи между гепсидином и названными показателями.Результаты. У пациентов контрольной группы выявлены нормальные уровни гепсидина (9,17±0,97 нг/мл) и единственная значимая связь гепсидина с показателем феррокинетики – сывороточным железом (r(S)=0,480, р=0,032). В группе ХСН без анемии выявлены также нормальные уровни гепсидина (12,01±1,19 нг/мл) и две значимые связи гепсидина с показателями феррокинетики – ферритином [r(S)=0,525, р=0,001] и трансферрином [r(S)=- 0,343, р=0,044]. В группе ХСН с АХЗ выявлены значимо повышенные уровни гепсидина (23,81±3,63 нг/мл) относительно ХСН без анемии (р=0,008) и контрольной группы (р=0,003) и пять значимых корреляций гепсидина с показателями гемограммы – гемоглобином [r (S)=-0,461, р=0,043] и средней концентрацией гемоглобина в эритроците [r(S)=-0,437, р=0,009]; феррокинетики – ферритином [r(S)=0,596, р&lt;0,0001] и трансферрином [r(S) =-0,474, р=0,004]; воспаления – СРБ [r(S)=0,561, p&lt;0,0001].Заключение. Повышенные уровни гепсидина у больных ХСН с АХЗ и образование связей гепсидина с показателями гемограммы и феррокинетики отражают его роль как регулятора метаболизма железа, а связь с показателем воспаления – его роль как медиатора воспаления, участвующего в развитии АХЗ у больных ХСН пожилого и старческого возраста.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гепсидин</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>анемия хронических заболеваний</kwd><kwd>пожилой и старческий возраст</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepcidin</kwd><kwd>chronic heart failure</kwd><kwd>anemia of chronic diseases</kwd><kwd>elderly and senile age</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено при поддержке Сеченовского Университета.</funding-statement><funding-statement xml:lang="en">The study was performed with the support of the Sechenov University</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J Biol Chem. 2001;276(11):7806-10. DOI:10.1074/jbc.M008922200.</mixed-citation><mixed-citation xml:lang="en">Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J Biol Chem. 2001;276(11):7806-10. DOI:10.1074/jbc.M008922200.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Camaschella С. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. DOI:10.1182/asheducation-2013.1.1.</mixed-citation><mixed-citation xml:lang="en">Camaschella С. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. DOI:10.1182/asheducation-2013.1.1.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Arezes J, Nemeth E. Hepcidin and Iron Disorders: New Biology and Clinical Approaches. Int J Lab Hematol. 2015;37(1):92-8. DOI:10.1111/ijlh.12358.</mixed-citation><mixed-citation xml:lang="en">Arezes J, Nemeth E. Hepcidin and Iron Disorders: New Biology and Clinical Approaches. Int J Lab Hematol. 2015;37(1):92-8. DOI:10.1111/ijlh.12358.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-3. DOI:10.1182/blood-2002-10-3235.</mixed-citation><mixed-citation xml:lang="en">Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-3. DOI:10.1182/blood-2002-10-3235.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-6. DOI:10.1172/JCI20945.</mixed-citation><mixed-citation xml:lang="en">Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-6. DOI:10.1172/JCI20945.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48(1):10-5. DOI:10.5045/br.2013.48.1.10.</mixed-citation><mixed-citation xml:lang="en">D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48(1):10-5. DOI:10.5045/br.2013.48.1.10.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012;338(6108):768-72. DOI:10.1126/science.1224577.</mixed-citation><mixed-citation xml:lang="en">Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012;338(6108):768-72. DOI:10.1126/science.1224577.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The Role of Inflammation and Cell Death in the Pathogenesis, Progression and Treatment of Heart Failure. Heart Fail Rev. 2016;21(2):169-76. DOI:10.1007/s10741-016-9533-z.</mixed-citation><mixed-citation xml:lang="en">Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The Role of Inflammation and Cell Death in the Pathogenesis, Progression and Treatment of Heart Failure. Heart Fail Rev. 2016;21(2):169-76. DOI:10.1007/s10741-016-9533-z.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Iron Regulatory Hormone Hepcidin Decreases in Chronic Heart Failure Patients With Anemia. Circ J. 2010;74(2):301-6. DOI:10.1253/circj.cj-09-0663.</mixed-citation><mixed-citation xml:lang="en">Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Iron Regulatory Hormone Hepcidin Decreases in Chronic Heart Failure Patients With Anemia. Circ J. 2010;74(2):301-6. DOI:10.1253/circj.cj-09-0663.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Anand IS, Rector TS. Pathogenesis of Anemia in Heart Failure. Circ Heart Fail. 2014;7(5):699-700. DOI:10.1161/CIRCHEARTFAILURE.114.001645.</mixed-citation><mixed-citation xml:lang="en">Anand IS, Rector TS. Pathogenesis of Anemia in Heart Failure. Circ Heart Fail. 2014;7(5):699-700. DOI:10.1161/CIRCHEARTFAILURE.114.001645.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI:10.1056/NEJMra041809. PMID: 15758012.</mixed-citation><mixed-citation xml:lang="en">Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI:10.1056/NEJMra041809. PMID: 15758012.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Leong W, Lönnerdal B. Hepcidin, the Recently Identified Peptide That Appears to Regulate Iron Absorption. J Nutr. 2004;134(1):1-4. DOI:10.1093/jn/134.1.1.</mixed-citation><mixed-citation xml:lang="en">Leong W, Lönnerdal B. Hepcidin, the Recently Identified Peptide That Appears to Regulate Iron Absorption. J Nutr. 2004;134(1):1-4. DOI:10.1093/jn/134.1.1.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dick SA, Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circ Res. 2016;119(1):159-76. DOI:10.1161/CIRCRESAHA.116.308030.</mixed-citation><mixed-citation xml:lang="en">Dick SA, Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circ Res. 2016;119(1):159-76. DOI:10.1161/CIRCRESAHA.116.308030.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hage C, Michaëlsson E, Linde C, et al. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction A Holistic Proteomic Approach. Circ Cardiovasc Genet. 2017;10(1):e001633. DOI:10.1161/CIRCGENETICS.116.001633.</mixed-citation><mixed-citation xml:lang="en">Hage C, Michaëlsson E, Linde C, et al. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction A Holistic Proteomic Approach. Circ Cardiovasc Genet. 2017;10(1):e001633. DOI:10.1161/CIRCGENETICS.116.001633.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Boulognea M, Sadouneb M, Launaybc JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53-59. DOI:10.1016/j.ijcard.2016.10.038.</mixed-citation><mixed-citation xml:lang="en">Boulognea M, Sadouneb M, Launaybc JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53-59. DOI:10.1016/j.ijcard.2016.10.038.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Putten K, Jie KE, Van den Broek D, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12(9):943-50. DOI:10.1093/eurjhf/hfq099.</mixed-citation><mixed-citation xml:lang="en">Van der Putten K, Jie KE, Van den Broek D, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12(9):943-50. DOI:10.1093/eurjhf/hfq099.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Divakaran V, Mehta S, Yao D, et al. Hepcidin in anemia of chronic heart failure. Am J Hematol. 2011;86(1):107-9. DOI:10.1002/ajh.21902.</mixed-citation><mixed-citation xml:lang="en">Divakaran V, Mehta S, Yao D, et al. Hepcidin in anemia of chronic heart failure. Am J Hematol. 2011;86(1):107-9. DOI:10.1002/ajh.21902.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jankowska ЕА, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827-34. DOI:10.1093/eurheartj/ehs377.</mixed-citation><mixed-citation xml:lang="en">Jankowska ЕА, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827-34. DOI:10.1093/eurheartj/ehs377.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Подзолков В.И., Драгомирецкая Н.А., Столбова С.К., Русинов И.С. Ассоциации уровней NT-proBNP и гепсидина с клинико-лабораторными параметрами у больных хронической сердечной недостаточностью с разной степенью систолической дисфункции левого желудочка. Кардиоваскулярная Терапия и Профилактика. 2020;19(4):2587. DOI:10.15829/1728-8800-2020-2587.</mixed-citation><mixed-citation xml:lang="en">Podzolkov VI, Dragomiretskaya NA, Stolbova SK, Rusinov IS. Associations of NT-proBNP and hepcidin levels with clinical and laboratory parameters in patients with heart failure with various severity of left ventricular systolic dysfunction. Cardiovascular Therapy and Prevention. 2020;19(4):2587 (In Russ.) DOI:10.15829/1728-8800-2020-2587.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nemeth E. Targeting the Hepcidin-Ferroportin Axis in the Diagnosis and Treatment of Anemias. Adv Hematol. 2010;2010:750643. DOI:10.1155/2010/750643.</mixed-citation><mixed-citation xml:lang="en">Nemeth E. Targeting the Hepcidin-Ferroportin Axis in the Diagnosis and Treatment of Anemias. Adv Hematol. 2010;2010:750643. DOI:10.1155/2010/750643.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Lanser L, Fuchs D, Scharnagl H, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021;8:666638. DOI:10.3389/fcvm.2021.666638.</mixed-citation><mixed-citation xml:lang="en">Lanser L, Fuchs D, Scharnagl H, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021;8:666638. DOI:10.3389/fcvm.2021.666638.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Muzzarelli S, Pfisterer M, TIME Investigators. Anemia as Independent Predictor of Major Events in Elderly Patients With Chronic Angina. Am Heart J. 2006;152(5):991-6. DOI:10.1016/j.ahj.2006.06.014.</mixed-citation><mixed-citation xml:lang="en">Muzzarelli S, Pfisterer M, TIME Investigators. Anemia as Independent Predictor of Major Events in Elderly Patients With Chronic Angina. Am Heart J. 2006;152(5):991-6. DOI:10.1016/j.ahj.2006.06.014.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Caughey MC, Avery CL, Ni H, et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am J Cardiol. 2014;114(12):1850-4. DOI:10.1016/j.amjcard.2014.09.024.</mixed-citation><mixed-citation xml:lang="en">Caughey MC, Avery CL, Ni H, et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am J Cardiol. 2014;114(12):1850-4. DOI:10.1016/j.amjcard.2014.09.024.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Muñoz M, García-Erce JA, Remacha AF. Disorders of Iron Metabolism. Part II: Iron Deficiency and Iron Overload. J Clin Pathol. 2011;64(4):287-96. DOI:10.1136/jcp.2010.086991.</mixed-citation><mixed-citation xml:lang="en">Muñoz M, García-Erce JA, Remacha AF. Disorders of Iron Metabolism. Part II: Iron Deficiency and Iron Overload. J Clin Pathol. 2011;64(4):287-96. DOI:10.1136/jcp.2010.086991.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cook JD. Diagnosis and Management of Iron-Deficiency Anaemia. Best Pract Res Clin Haematol. 2005;18(2):319-32. DOI:10.1016/j.beha.2004.08.022.</mixed-citation><mixed-citation xml:lang="en">Cook JD. Diagnosis and Management of Iron-Deficiency Anaemia. Best Pract Res Clin Haematol. 2005;18(2):319-32. DOI:10.1016/j.beha.2004.08.022.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron Therapy in Patients With Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. Am J Cardiovasc Drugs. 2017;17(3):183-201. DOI:10.1007/s40256-016-0211-2.</mixed-citation><mixed-citation xml:lang="en">Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron Therapy in Patients With Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. Am J Cardiovasc Drugs. 2017;17(3):183-201. DOI:10.1007/s40256-016-0211-2.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35. DOI:10.1053/j.ajkd.2014.01.416.</mixed-citation><mixed-citation xml:lang="en">Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35. DOI:10.1053/j.ajkd.2014.01.416.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 29(4):1165-1188. DOI:10.1214/aos/1013699998.</mixed-citation><mixed-citation xml:lang="en">Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 29(4):1165-1188. DOI:10.1214/aos/1013699998.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of Anemia in Patients With Advanced Heart Failure. J Am Coll Cardiol. 2006;48(12):2485-9. DOI:10.1016/j.jacc.2006.08.034.</mixed-citation><mixed-citation xml:lang="en">Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of Anemia in Patients With Advanced Heart Failure. J Am Coll Cardiol. 2006;48(12):2485-9. DOI:10.1016/j.jacc.2006.08.034.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13-14):411-423. DOI:10.1007/s10354-016-0505-7.</mixed-citation><mixed-citation xml:lang="en">Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13-14):411-423. DOI:10.1007/s10354-016-0505-7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nagai T, Nishimura K, Honma T, et al., NaDEF investigators. Prognostic Significance of Endogenous Erythropoietin in Long-Term Outcome of Patients With Acute Decompensated Heart Failure. Eur J Heart Fail. 2016;18(7):803-13. DOI:10.1002/ejhf.537.</mixed-citation><mixed-citation xml:lang="en">Nagai T, Nishimura K, Honma T, et al., NaDEF investigators. Prognostic Significance of Endogenous Erythropoietin in Long-Term Outcome of Patients With Acute Decompensated Heart Failure. Eur J Heart Fail. 2016;18(7):803-13. DOI:10.1002/ejhf.537.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29(3):327-35. DOI:10.1006/bcmd.2002.0573.</mixed-citation><mixed-citation xml:lang="en">Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29(3):327-35. DOI:10.1006/bcmd.2002.0573.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Wendy PJ, den Elzen, Anton JM, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.</mixed-citation><mixed-citation xml:lang="en">Wendy PJ, den Elzen, Anton JM, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Cowie MR, Wood DA, Coats AJ, et al. Survival of Patients With a New Diagnosis of Heart Failure: A Population Based Study. Heart. 2000;83(5):505-10. DOI:10.1136/heart.83.5.505.</mixed-citation><mixed-citation xml:lang="en">Cowie MR, Wood DA, Coats AJ, et al. Survival of Patients With a New Diagnosis of Heart Failure: A Population Based Study. Heart. 2000;83(5):505-10. DOI:10.1136/heart.83.5.505.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Picca A, Mankowski RT, Kamenov G, et al. Advanced Age Is Associated with Iron Dyshomeostasis and Mitochondrial DNA Damage in Human Skeletal Muscle. Cells. 2019;8(12):1525. DOI:10.3390/cells8121525.</mixed-citation><mixed-citation xml:lang="en">Picca A, Mankowski RT, Kamenov G, et al. Advanced Age Is Associated with Iron Dyshomeostasis and Mitochondrial DNA Damage in Human Skeletal Muscle. Cells. 2019;8(12):1525. DOI:10.3390/cells8121525.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Suega K, Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease. Hematol Transfus Cell Ther. 2019;41(4):342-348. DOI:10.1016/j.htct.2019.03.011.</mixed-citation><mixed-citation xml:lang="en">Suega K, Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease. Hematol Transfus Cell Ther. 2019;41(4):342-348. DOI:10.1016/j.htct.2019.03.011.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18(7):881. DOI:10.1002/ejhf.588.</mixed-citation><mixed-citation xml:lang="en">Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18(7):881. DOI:10.1002/ejhf.588.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ларина В.Н., Барт Б.Я., Балабанова Э.Л. Анемический синдром у больных с хронической сердечной недостаточностью. Российский Кардиологический Журнал. 2010;(3):34-40.</mixed-citation><mixed-citation xml:lang="en">Larina VN, Bart BYa, Balabanova EL. Anemic syndrome in patients with chronic heart failure. Russian Journal of Cardiology. 2010;(3):34-40 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных больных декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы больных. Сердечная Недостаточность. 2014;82(1):23-32.</mixed-citation><mixed-citation xml:lang="en">Arutyunov AG, Rylova AK, Arutyunov GP. Register of hospitalized patients with circulatory decompensation (Pavlovsky register). Message 1. Modern clinical characteristics of a patient with circulatory decompensation. Clinical phenotypes of patients. Heart Failure. 2014;82(1):23-32 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ткаченко Е.И., Боровкова Н.Ю., Буянова М.В., Боровков Н.Н. Цитокин-индуцированное воспаление при анемии у больных хронической сердечной недостаточностью. Клиническая медицина. 2020;98(2):122-9. DOI:10.30629/0023-2149-2020-98-2-122-129.</mixed-citation><mixed-citation xml:lang="en">Tkachenko EI, Borovkova NYu, Buyanova MV, Borovkov NN. Cytokine-induced inflammation in anemia in patients with chronic heart failure. Clinical Medicine (Russian Journal). 2020;98(2):122-9 (In Russ.). DOI:10.30629/0023-2149-2020-98-2-122-129.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">den ElzenWP, deCraen AJ, Wiegerinck ET, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.</mixed-citation><mixed-citation xml:lang="en">den ElzenWP, deCraen AJ, Wiegerinck ET, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
